Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
- DOI
- 10.1038/s41523-022-00467-1
- Published
- 2022 Aug 29
- Container
- NPJ breast cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41523-022-00467-1,
title = {Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.},
author = {Rugo HS and Tolaney SM and Loirat D and Punie K and Bardia A and Hurvitz SA and O'Shaughnessy J and Cortés J and Diéras V and Carey LA and Gianni L and Piccart MJ and Loibl S and Goldenberg DM and Hong Q and Olivo M and Itri LM and Kalinsky K},
year = {2022},
journal = {NPJ breast cancer},
doi = {10.1038/s41523-022-00467-1},
url = {https://doi.org/10.1038/s41523-022-00467-1}
}RIS
TY - JOUR TI - Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. AU - Rugo HS AU - Tolaney SM AU - Loirat D AU - Punie K AU - Bardia A AU - Hurvitz SA AU - O'Shaughnessy J AU - Cortés J AU - Diéras V AU - Carey LA AU - Gianni L AU - Piccart MJ AU - Loibl S AU - Goldenberg DM AU - Hong Q AU - Olivo M AU - Itri LM AU - Kalinsky K PY - 2022 JO - NPJ breast cancer DO - 10.1038/s41523-022-00467-1 UR - https://doi.org/10.1038/s41523-022-00467-1 ER -
APA
HS, R., SM, T., D, L., K, P., A, B., SA, H., J, O., J, C., V, D., LA, C., L, G., MJ, P., S, L., DM, G., Q, H., M, O., LM, I., & K, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.. NPJ breast cancer. https://doi.org/10.1038/s41523-022-00467-1
Source records
- pubmed · retrieved 2026-09-26T23:08:53.098Z
- europe-pmc · retrieved 2026-09-26T23:08:53.106Z
- doaj · retrieved 2026-09-26T23:08:53.108Z